Thursday, December 3 | 8:00 a.m.-9:00 a.m. | R1-SSNMMI07-4 | Room S405
PET/CT with a novel radiotracer initially developed for amyloid imaging in Alzheimer’s disease may detect and help subtype cardiac amyloidosis, suggest preliminary findings from a small clinical evaluation presented in this session.
In an early evaluation of the investigational tracer, Ines Valenta, MD, of Washington University in St. Louis, MO, and colleagues enrolled six patients (mean age 66 years): one with multiple myeloma and no suspected cardiac involvement, two with light chain (AL) amyloidosis, and three with transthyretin-mediated amyloidosis (ATTR). Each patient underwent a 60-minute dynamic cardiac F-18 fluselenamyl (F-18 FSA) PET/CT scan plus a 10-minute static scan at 60 minutes. Myocardial uptake was assessed visually on a five-point scale and quantitatively by SUVmax.
The patient with multiple myeloma showed no myocardial F-18 FSA uptake. Both AL patients demonstrated cardiac uptake (SUVmax 3.5 and 6.5, respectively); one also showed intense F-18 FSA uptake in the blood pool, which the team interpreted as potentially reflecting circulating light chains in an earlier disease state. All three ATTR patients showed cardiac uptake: patchy and moderate in one wild-type patient (mean SUVmax 6), diffuse and intense in the second (mean SUVmax 7), and diffuse and intense in a variant ATTR patient (mean SUVmax 7).
Differentiating AL from ATTR is diagnostically challenging despite its clinical importance, as the subtypes require different treatments, and current imaging approaches have limitations in non-invasive subtyping, the researchers noted.
"These preliminary results may indeed suggest F-18 FSA as a potential PET radiotracer for the non-invasive identification and characterization of cardiac amyloidosis and subtypes that deserve further clinical explorations," the group wrote.
Check out this session to learn all the details.



